



 **APhA2016**
Expanding Opportunities
through Patient Care
Annual Meeting & Exposition
Baltimore, MD March 4-7



New Business Review Committee Report

Baltimore, Maryland
March 5, 2016

The APhA House of Delegates New Business Review Committee met on Saturday, March 5, 2016, and presents the following report:

The APhA New Business Review Committee recommends **ADOPTION** of New Business Item #1 as **amended**.

Drug Abuse Substance Use Disorder Education

APhA supports comprehensive drug abuse substance use disorder education, prevention, treatment, and rehabilitation recovery programs-consisting of education and rehabilitation.

Adequacy of Directions for Use on Prescriptions and Prescription Orders

The APhA New Business Review Committee Recommends **REJECTION** of New Business Item #2, Whole Number Statement #1.

1. APhA recommends that all professions with prescriptive authority address the issue of prescribers' responsibility for specific instructions to the pharmacist and the patient in all prescription orders, including order clarification when sought by the pharmacist.

The APhA New Business Review Committee Recommends **REJECTION** of New Business Item #2, Whole Number Statement #2.

2. APhA affirms the pharmacist's responsibility, as the patient's advocate, to obtain and communicate adequate directions for use of medications.

Substance Use Disorder Combating Drug Abuse

The APhA New Business Review Committee Recommends **ADOPTION** of New Business Item #3, Whole Number Statement #1 as **amended**.

1. APhA supports legislative, regulatory, and private sector efforts that include input from pharmacists to balance the need for patient/consumer access to medications for legitimate medical purposes with the need to prevent diversion and **abuse-misuse**.

The APhA New Business Review Committee Recommends **ADOPTION** of New Business Item #3, Whole Number Statement #2 as **written**.

2. APhA supports consumer sales limits of nonprescription drug products that may be illegally converted into drugs for illicit use such as methamphetamine precursors.

The APhA New Business Review Committee Recommends **ADOPTION** of New Business Item #3, Whole Number Statement #3 as **amended**.

3. APhA encouraged education of all personnel involved in the distribution chain of nonprescription products concerning the potential for certain products, such as methamphetamine precursors, to be illegally converted into drugs for illicit use. APhA supports patient/consumer education of consequences of methamphetamine **abuse-misuse**.

The APhA New Business Review Committee Recommends **ADOPTION** of New Business Item #3, Whole Number Statement #4 as **amended**.

4. APhA supports public and private initiatives that result in increased funding to address the escalating needs for **drug-abuse-substance use disorder** treatment and prevention.

The APhA New Business Review Committee Recommends **ADOPTION** of New Business Item #3, Whole Number Statement #5 as **written**.

5. APhA supports stringent enforcement of criminal laws against individuals who engage in the trafficking of illicit drugs including methamphetamine and methamphetamine precursors.

Legalization or Decriminalization of Illicit Drugs

The APhA New Business Review Committee Recommends **ADOPTION** of New Business Item #4, Whole Number Statement #1 as **amended**.

1. APhA opposes legalization or ~~decriminalization~~ of the possession, sale, distribution, or use of **illicit** drug substances for non-medical uses.

The APhA New Business Review Committee Recommends **ADOPTION** of New Business Item #4, Whole Number Statement #2 as **written**.

2. APhA supports the use of drug courts or other evidence-based mechanisms, when appropriate as determined by the courts, to provide alternate pathways within the criminal justice system for the treatment and rehabilitation of individuals charged with illicit drug-related offenses who have substance abuse or other related medical disorders.

The APhA New Business Review Committee recommends **ADOPTION** of New Business Item #4, Whole Number Statement #3 as **amended**.

3. APhA supports criminal penalties for persons convicted of drug-related crimes including, but not limited to, ~~illicit~~ drug trafficking, drug manufacturing, and drug diversion whenever alternate pathways are inappropriate as determined by the courts.

The APhA New Business Review Committee recommends **REFERRAL** of New Business Item #5.

Generic Solid Dosage Forms

APhA encourages the FDA, USP and other appropriate organizations and agencies to standardize the identification and appearance of generic solid dosage forms.

The APhA New Business Review Committee recommends **REJECTION** of New Business Item #6.

Biotechnology

APhA supports legislation or regulation that requires all phases of clinical data on biosimilar and small molecule generics to be made available on clinicaltrials.gov and published in peer reviewed and retrievable literature.

The APhA New Business Review Committee recommends **REJECTION** of New Business Item #7.

Food and Drug Administration (FDA) Authorization for Selected Medications/Dosage Forms to be Available Without a Prescription from a Pharmacist.

APhA urges the FDA to authorize the following medications/dosage forms to be available without a prescription from a pharmacist:

- Naloxone for opioid overdose
- Epinephrine auto-injectors for severe allergic reactions
- Albuterol for oral inhalation for acute asthma attacks
- Nitroglycerin for sublingual use for symptoms of a heart attack
- Varenicline for smoking cessation

The APhA New Business Review Committee recommends **ADOPTION** of New Business Item #8 as **amended**.

Drug Disposal

APhA encourages increasing the number percentage of available pharmacies that voluntarily register as collection sites to expand patient access to disposal locations in a secure, convenient, and responsible manner in accordance with the Federal Secure and Responsible Drug Disposal Act of 2010 and related regulations.

Medication Assisted Treatment

The APhA New Business Review Committee recommends **ADOPTION** of New Business Item #9, Whole Number Statement #1 as **amended**.

1. APhA supports pharmacists expanding access to Medication Assisted Treatment (MAT), including but not limited to by establishing pharmacist administered based injection services for substance use disorder opioid abuse treatment and / maintenance based on a valid prescription.

The APhA New Business Review Committee recommends **REJECTION** of New Business Item #9, Whole Number Statement #2.

2. APhA supports pharmacists creating a system of care working in collaboration with the physician, behavioral health counselors and other health care providers to provide integrated patient centered care.

Opioid Overdose Prevention

The APhA New Business Review Committee recommends **ADOPTION** of New Business Item #10, Whole Number Statement #1 as **amended**.

1. APhA supports access to, ~~coverage of, and payment for~~ third-party ~~caregiver~~ (non-patient recipient) prescriptions ~~and dispensing of for~~ opioid reversal agents furnished by, issued as a prescription, or by standing order, collaborative practice agreement, or other legal or regulatory mechanism to increase opioid reversal agent distribution via pharmacists.

The APhA New Business Review Committee recommends **ADOPTION** of New Business Item #10, Whole Numbered Statement #2 as **amended**.

2. APhA affirms that third-party (non-patient recipient) prescriptions ~~are issued for legitimate medical purposes and should~~ be reimbursed by public and private payers ~~for members who seek to protect their communities, friends, and family members exactly as prescriptions issued to members with risk factors for opioid overdose~~.

Labeling and Measurement of Oral Liquid Medications

The APhA New Business Review Committee recommends ADOPTION of New Business Item #11, Whole Number Statement #1 as written.

1. APhA supports the use of the milliliter (mL) as the standard unit of measure for oral liquid medications.

The APhA New Business Review Committee recommends ADOPTION of New Business Item #11, Whole Number Statement #2 as written.

2. APhA encourages the mandatory use of leading zeros before the decimal point for amounts less than one on prescription container labels for oral liquid medications.

The APhA New Business Review Committee recommends ADOPTION of New Business Item #11, Whole Number Statement #3 as written.

3. APhA discourages the use trailing zeros after the decimal point for amounts greater than one on prescription container labels for oral liquid medications.

The APhA New Business Review Committee recommends ADOPTION of New Business Item #11, Whole Number Statement #4 as written.

4. APhA supports access to and universal availability of dosing devices with numeric graduations that correspond to the unit of measure on the container labeling for oral liquid medications.